US · Healthcare · Biotechnology
EPS came in at -1.06 against a street estimate of -0.88 — a miss of 20.5%.
Analysts rate Dyne Therapeutics Inc a strong buy (15 buy, 1 hold, 1 sell out of 17) with an average price target of $34.33.
| Fund | Stake |
|---|---|
| T. Rowe Price Investment Management,Inc. | 16.56% |
| BlackRock Inc | 6.64% |
| Jupiter Topco LLC | 6.43% |
| FMR Inc | 6.00% |
| State Street Corp | 3.99% |
| Orbis Allan Gray Ltd | 3.75% |
| Atlas Venture Life Science Advisors, LLC | 3.64% |
| Vanguard Capital Management, LLC | 3.38% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Dyne Therapeutics is a clinical-stage biotechnology company developing treatments for genetically driven neuromuscular diseases. | 2026-11-05 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Cash, cash equivalents and marketable securities were $1.134 billion as of September 30, 2026, expected to fund operations into th | 2026-11-05 |
| Reg FD disclosure · Q3 2026 HEADLINE NUMBERS • Dyne Therapeutics reported additional one-year clinical data for z-basivarsen (DYNE-101) in the Phase 1/2 ACHIEVE trial for myotoni | 2026-09-29 |
| Quarterly report · Q2 2026 DYNE THERAPEUTICS, INC. – 10-Q SUMMARY FOR RETAIL INVESTORS Period Ended June 30, 2026 --- HEADLINE NUMBERS • Cash Position: $676.1 million in cash | 2026-07-29 |
| Results announced · Q3 2026 DYNE THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Net loss for Q2 2026: $178.6 million ($1.08 per share) vs. $110.9 million ($0 | 2026-07-29 |
| Material agreement · Q3 2026 DYNE THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Public offering size: 18,300,000 shares at $20.50 per share • Net proceeds (base case): App | 2026-07-22 |
| Company announcement · Q3 2026 DYNE THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • FDA Priority Review Granted for zeleciment rostudirsen (z-rostudirsen/DYNE-251) biologics l | 2026-07-20 |
| Board / officer change · Q2 2026 DYNE THERAPEUTICS, INC. – 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Dyne Therapeutics is a Delaware-incorporated company trading under ticker symb | 2026-06-22 |
Readable in the app.
| Announcement | Date |
|---|---|
| Completion of enrollment in registrational trial; topline data planned Q1 2027 Dyne Therapeutics announced it has completed enrollment of 71 participants in the registrational expansion cohort (REC) of its ACHIEVE trial testing z-basivarsen (DYNE-101) for myotonic dyst | 2026-06-03 |
| BLA submission Q2 2026, potential launch Q1 2027 for z-rostudirsen Dyne Therapeutics reported Q1 2026 results with significant progress on two lead drug candidates for rare genetic neuromuscular diseases. For z-rostudirsen (treating Duchenne muscular dystro | 2026-05-11 |
| Accelerated Approval submission planned Q2 2026; potential launch Q1 2027 Dyne Therapeutics, a clinical-stage biotech company, reported encouraging progress on two lead drug candidates for rare neuromuscular diseases. Their main drug, z-rostudirsen (for Duchenne m | 2026-03-02 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Dyne Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.